Triplet Regimen Offers Improved Outcomes in BRAF-Mutant Colorectal Cancer

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

In a phase III clinical trial, a triple-drug therapy nearly triples overall survival for patients with colorectal cancer.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.